• Sanofi Genzyme to Present New Data on MS Treatments Lemtrada and Aubagio
  • Diplomat Pharmacy to Distribute Recently Approved PARP Inhibitor Zejula in the US
  • Why the Future of Science Is Crucial to the MS Community
  • The Importance of Clinical Trials in SMA
  • Cure SMA to Host May 4 Webinar on Spinraza Access, Insurance Coverage and Trial Results
  • Abemaciclib Combo Seen to Slow Progression in Phase 3 Advanced Breast Cancer Trial
  • Bioinformatics Approach Identifies Potential Therapies Targeting TNF, a Factor in MS, Other Diseases
  • Dispelling Three Common Endometriosis Myths
  • Mayo Clinic Neurologist Explains Probable Cause of Multiple Sclerosis
  • Latest Tecfidera and Tysabri Data Suggest Treatments Improve MS Outcomes When Used Early
  • Chronic Illness and End-of-Life Decisions: Who are We to Judge?
  • AbbVie’s Veliparib and Chemotherapy Combo Trial Failed in Early Triple Negative Breast Cancer